(NASDAQ: MYGN) Myriad Genetics's forecast annual revenue growth rate of 7.86% is forecast to beat the US Diagnostics & Research industry's average forecast revenue growth rate of 5.91%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 9.25%.
Myriad Genetics's revenue in 2024 is $774,200,000.On average, 5 Wall Street analysts forecast MYGN's revenue for 2024 to be $75,333,412,906, with the lowest MYGN revenue forecast at $74,669,084,325, and the highest MYGN revenue forecast at $75,728,027,703. On average, 5 Wall Street analysts forecast MYGN's revenue for 2025 to be $81,454,286,645, with the lowest MYGN revenue forecast at $80,523,140,536, and the highest MYGN revenue forecast at $82,561,380,268.
In 2026, MYGN is forecast to generate $87,781,699,596 in revenue, with the lowest revenue forecast at $84,772,490,244 and the highest revenue forecast at $89,955,882,316.